Personalized T-cell therapy for advanced liver cancer
Part of Cancer clinical trials.
This trial tests a personalized treatment using your own immune cells (T-cells) trained to attack specific markers on your liver cancer. It is for people with advanced liver cancer that has worsened after at least two prior treatments and who have tumor tissue available for genetic testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced liver cancer that can be measured on scans and has gotten worse after at least two previous treatments
- You have tumor tissue (or prior genetic sequencing data) available for testing
- Your liver, kidney, and blood counts are within acceptable ranges
- You do not have an active infection like hepatitis B or C, HIV, or syphilis
- You are not taking high-dose steroids or have an autoimmune disease that requires them
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
This trial tests a new type of immune cell therapy (multi-target Hi-TCR-T cells) for people with advanced liver cancer that hasn't responded to earlier treatments. The therapy targets several markers on your cancer cells to try to attack the tumor more effectively.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.